復銳醫療(01696.HK)附屬Alma HK訂立資產購買協議 涉2.7億人民幣
復銳醫療(01696.HK)公布,附屬公司Alma HK與賣方PhotonMed HK及擁有人訂立資產購買協議,收購賣方在中國進行的有關Alma Lasers產品分銷的所有業務活動,收購代價2.7億元人民幣。
Alma HK與PhotonMed HK、擁有人及Alma Lasers訂立股東協議,擬向PhotonMed HK發行40%股份,完成後Alma Lasers及PhotonMed HK將分別持有Alma HK已發行股份總數的60%及40%。
復銳醫療認為,交易將有利於AlmaLasers控制重要的直銷渠道並提升盈利能力,可進一步提升Alma Lasers的市場領導地位。(gc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.